Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/113682
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWabe, N.en
dc.contributor.authorSorich, M.en
dc.contributor.authorWechalekar, M.en
dc.contributor.authorCleland, L.en
dc.contributor.authorMcWilliams, L.en
dc.contributor.authorLee, A.en
dc.contributor.authorHall, C.en
dc.contributor.authorSpargo, L.en
dc.contributor.authorMetcalf, R.en
dc.contributor.authorProudman, S.en
dc.contributor.authorWiese, M.en
dc.date.issued2016en
dc.identifier.citationInternational Journal of Clinical Practice, 2016; 70(4):340-350en
dc.identifier.issn1368-5031en
dc.identifier.issn1742-1241en
dc.identifier.urihttp://hdl.handle.net/2440/113682-
dc.description.abstractAim: While the introduction of the treat-to-target (T2T) strategy has been an important advance in the management of rheumatoid arthritis (RA), the potential for increased toxicity due to use of concurrent drugs could adversely affect patient reported outcomes (PROs). The objective was to determine whether the cessation of therapy due to toxicity affects long-term improvement in PROs in patients treated according to T2T strategy. Methods: A total of 149 patients from an inception cohort of early RA were included. The occurrence and severity of toxicity were monitored at each visit over 3 years. PROs studied were function (measured using health assessment questionnaire); pain, fatigue and patient global assessment (PtGA) all assessed using a 100 mm visual analogue scale; helplessness and health-related quality of life (HRQoL). For each PRO, effect of drug withdrawal was measured by comparing mean change in PROs among patients with no/temporary vs. permanent withdrawal. In addition, effects of frequency of drug withdrawals, weeks to withdrawal and number of drugs withdrawn were analysed using linear regression. Result: After 3 years, 56 (37.4%) patients ceased at least one drug permanently due to toxicity. Patients with no/temporary withdrawal (n = 93) achieved significantly greater improvement in function (mean change = -0.54 vs. -0.31, p = 0.033), pain (mean change = -39.82 vs. -5.02, p = 0.018), fatigue (mean change = -29.14 vs. -14.76, p = 0.015) and PtGA (mean change = -29.64 vs. -17.00, p = 0.018) compared with their counterparts. Higher frequency of withdrawals was associated with lesser improvements in function, pain, fatigue and PtGA, while the number of drugs withdrawn and the weeks to withdrawal had lesser effects. However, the cessation of the drugs due to their toxicity did not have a significant association with HRQoL and helplessness. Conclusion: Improvements in function, pain, fatigue and PtGA at 3 years were diminished for patients who ceased drugs due to toxicity while broader measures of HRQoL were not affected.en
dc.description.statementofresponsibilityN. Wabe, M.J. Sorich, M.D. Wechalekar, L.G. Cleland, L. McWilliams, A. Lee, C. Hall, L. Spargo, R. Metcalf, S.M. Proudman, M.D. Wieseen
dc.language.isoenen
dc.publisherWileyen
dc.rights© 2016 John Wiley & Sons Ltden
dc.subjectPatient Reported Outcome Measuresen
dc.titleDrug-induced toxicity and patient reported outcomes in rheumatoid arthritis patients following intensive treated-to-target strategy: does ceasing therapy due to toxicity worsen outcomes in long term?en
dc.typeJournal articleen
dc.identifier.doi10.1111/ijcp.12785en
pubs.publication-statusPublisheden
dc.identifier.orcidProudman, S. [0000-0002-3046-9884]en
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.